SEC levies no fine against Kiromic BioPharma after material omissions self-disclosure
By 
Aaron Nicodemus2024-12-03T17:48:00
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission (SEC) after self-reporting that it failed to disclose material information about two cancer drugs to investors.
Houston-based Kiromic raised $40 million in a July 2021 public offering to fund clinical trials for two cancer drugs, but failed to alert investors that the U.S. Food and Drug Administration (FDA) had placed holds on clinical trials two weeks before the offering, the SEC said Tuesday in a press release. The company failed to report the FDA holds in two SEC filings, and failed to correct statements made by executives in roadshow calls with investors, according to the agency.
The allegations came to light after two anonymous complaints were filed on the company’s whistleblower hotline in August 2021, the SEC said.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
WebcastWebcast: The DOJ’s Corporate Whistleblower Program: What we’ve learned and how it can change in the future
We will discuss the critical role whistleblowers play in law enforcement, and how the DOJ has structured its program to incentivize people to come forward.
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
More from Regulatory Enforcement
-
ArticleFTC suit against Uber gains traction with 21 states and DC joining in
The Federal Trade Commission allegations against Uber, alleging deceptive billing and subscription cancellations, have snowballed, with 21 states and the District of Columbia joining the lawsuit.
-
ArticleTop Ethics and Compliance Failures of 2025
The 2025 year has been so rich with compliance stinkers, and rife with poor judgment, compliance missteps, outright malfeasance and greed, greed, greed, that it was almost impossible to choose just six epic compliance failures from this year’s massive poop pile.
-
ArticleFATF focus on criminal asset recovery points to a more investigatory role for compliance
Global organised crime is booming, and only 1 to 2 percent of the $4 trillion black economy is intercepted, according to figures from the Financial Action Task Force. Its new guidance suggests that countries should focus on rapid investigations, collaborative intelligence gathering, and confiscating the proceeds of criminal activity.